Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Calliditas
Calliditas
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Tarpeyo
Budesonide
2021-12-15
2026-2043
Chronic obstructive pulmonary disease
,
Asthma
,
Inflammatory bowel diseases
,
Allergic rhinitis perennial
,
Bronchial spasm
,
Hyperhidrosis
,
Iga glomerulonephritis
,
Esophageal diseases
,
Respiratory tract diseases
,
Peptic ulcer
,
Drug-induced abnormalities
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Budesonide
asthma
SETANAXIB
biliary liver cirrhosis
,
cholangitis
,
diabetic nephropathies
,
albuminuria
,
type 2 diabetes mellitus
,
diabetes mellitus
,
carcinoma
,
squamous cell carcinoma of head and neck
,
squamous cell carcinoma
,
hereditary nephritis
GKT137831
biliary liver cirrhosis
,
cholangitis
,
diabetic nephropathies
,
albuminuria
,
type 2 diabetes mellitus
,
diabetes mellitus
,
hereditary nephritis
Nefecon
kidney diseases
,
iga glomerulonephritis
,
chronic kidney failure
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use